Biochemical, anthropometric and body composition indicators as predictors of hepatic steatosis in obese adolescents

Indicadores bioquímicos, antropométricos e de composição corporal como preditores da esteatose hepática em adolescentes obesos

Indicadores bioquímicos, antropométricos y de composición corporal como predictores de la esteatosis hepática en adolescentes obesos

Amanda Oliva Gobato¹, Ana Carolina J. Vasques¹, Roberto Massao Yamada¹, Mariana Porto Zambon¹, Antonio de Azevedo Barros-Filho¹, Gabriel Hessel¹

ABSTRACT

Objective: To describe the prevalence of hepatic steatosis and to assess the performance of biochemical, anthropometric and body composition indicators for hepatic steatosis in obese teenagers.

Methods: Cross-sectional study including 79 adolescents aged from ten to 18 years old. Hepatic steatosis was diagnosed by abdominal ultrasound in case of moderate or intense hepatorenal contrast and/or a difference in the histogram ≥7 on the right kidney cortex. The insulin resistance was determined by the Homeostasis Model Assessment–Insulin Resistance (HOMA-IR) index for values >3.16. Anthropometric and body composition indicators consisted of body mass index, body fat percentage, abdominal circumference and subcutaneous fat. Fasting glycemia and insulin, lipid profile and hepatic enzymes, such as aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase and alkaline phosphatase, were also evaluated. In order to assess the performance of these indicators in the diagnosis of hepatic steatosis in teenagers, a ROC curve analysis was applied.

Results: Hepatic steatosis was found in 20% of the patients and insulin resistance, in 29%. Gamma-glutamyltransferase and HOMA-IR were good indicators for predicting hepatic steatosis, with a cutoff of 1.06 times above the reference value for gamma-glutamyltransferase and 3.28 times for the HOMA-IR. The anthropometric indicators, the body fat percentage, the lipid profile, the glycemia and the aspartate aminotransferase did not present significant associations.

Conclusions: Patients with high gamma-glutamyltransferase level and/or HOMA-IR should be submitted to abdominal ultrasound examination due to the increased chance of having hepatic steatosis.

Key-words: fatty liver; obesity; adolescent; enzymes.

RESUMO

Objetivo: Descrever a prevalência da estatose hepática e avaliar o desempenho de indicadores bioquímicos, antropométricos e de composição corporal para identificar a doença em adolescentes obesos.

Métodos: Estudo transversal com 79 adolescentes de dez a 18 anos. Diagnosticou-se a estatose hepática por ultrassom abdominal em caso de contraste hepatorenal moderado ou intenso e/ou diferença no histograma ≥7 em relação ao córtex do rim direito. Determinou-se a resistência à insulina pelo índice Homeostasis Model Assessment–Insulin Resistance (HOMA-IR) para valores >3,16. Os indicadores antropométricos e de composição corporal foram: índice de massa corpórea, porcentagem de gor-
dura corporal, circunferencia abdominal e gordura subcutânea. Dosaram-se glicemia e insulina de jejum, perfil lipídico e enzimas hepáticas aspartato aminotransferase, alanina aminotransferase, gama-glutamiltransferase e fosfatase alcalina. Aplicou-se a curva ROC para avaliar o desempenho dos indicadores para identificar adolescentes com esteatose hepática.

Resultados: A esteatose hepática esteve presente em 20% dos pacientes e a resistência à insulina, em 29%. A gama-glutamiltransferase e o HOMA-IR mostraram-se bons indicadores para predizer a esteatose hepática, com ponto de corte de 1,06 vezes acima do valor de referência para a gama-glutamiltransferase e de 3,28 para o HOMA-IR. Os indicadores antropométricos, a porcentagem de gordura corporal, o perfil lipídico, a glicemia e a aspartato aminotransferase não apresentaram diferenças significantes.

Conclusões: Pacientes com elevação de gama-glutamiltransferase e/ou HOMA-IR devem ser submetidos ao exame de ultrassom abdominal, havendo grande probabilidade de se obter como resultado a esteatose hepática.

Palavras-chave: fígado gorduroso; obesidade; adolescente; enzimas.
treated from April 2011 to May 2012 who presented body mass index (BMI) $\geq 97$ for age and sex, according to the charts of the World Health Organization (WHO)\(^6\), were invited to participate in the research. We analyzed the clinical, laboratory, and ultrasonography characteristics of 79 patients of both sexes, from 10 to 18 years old, who were diagnosed with obesity and whose parents signed an informed consent form (ICF).

Anthropometric techniques for measuring weight and height were those recommended by Lohman \textit{et al}\(^7\). We calculated BMI by the Quetelet index (BMI = weight/height\(^2\)). Waist circumference (WC) was measured in centimeters with tape measure (Sanny\®), at the midpoint between the last rib and the superior border of the iliac crest. The percentage of body fat (\%BF) was measured by dual energy X-ray absorptiometry (DXA), with Hologic\® appliance, Discovery QDR Series n. 1005-75.

Insulin resistance was diagnosed by Homeostasis Model Assessment-Insulin Resistance (HOMA-IR), which is the product of fasting insulin (mUI/mL) and fasting plasma glucose (mmol/L) divided by 22.5. Insulin Resistance was defined when the values were above 3.16\(^8\).

We carried out the ultrasonography by a Toshiba device, Power Vision 6000, through sector transducers of 3.75MHz and 5MHz. All exams were performed by the same examiner, with the patient in supine position after fasting for 12 hours. The diagnosis of HS was considered in case of moderate or severe hepatic steatosis. A sector transducer was positioned in the right upper quadrant of abdomen. The transducer was focused on the outer face of the fascia of the rectus abdominis muscles to avoid artifacts and to explore the subcutaneous fat layer completely. The transducer was positioned in the right lobe of the liver and the right kidney. The measurements were performed in triplicate and only the values closest to the mean were considered. We used the Kolmogorov-Smirnov test to assess the normality of the distribution of studied variables. We used the Mann-Whitney test to compare two independent groups. The hypothesis of dependence between categorical variables was assessed using the chi-square or Fischer’s exact test, according to the expected frequencies. We calculated the values for Odds Ratio (OR) and their respective confidence intervals of 95% (95%CI) to assess the strength of dependence between categorical variables.

The analysis of ROC curves (Receiver Operating Characteristic Curve) was used to assess the performance of the anthropometric and biochemical indicators in identifying adolescents with HS. Given the differences of values of the hepatic enzymes according to age and sex in the analyzed adolescents, the values of these enzymes were transformed in number of times the upper limit of normality (n’ x). That is, the result of the serum concentration of the hepatic enzyme was divided by the number of the reference value according to age and sex. We considered the reference value for each sex and age range and divided the value found by the reference value. We used as reference the values preconized by Roche Diagnostics\®\(^9\). The areas under the ROC curves were calculated as proposed by Hanley and McNeil. We used a confidence interval of 95%. The sensibility and specificity values were calculated for all variables in the analysis of the ROC curves with significant results. The cutoff point with the highest sum of sensitivity and specificity was chosen to optimize the relationship between these two parameters, reflecting greater accuracy in diagnosis.

The Kappa (k) test was used as a measure of agreement between the ultrasound (US) and the FLI. The k value reflects the degree of concordance between the methods. Values of k equal to 1 indicate perfect agreement between both methods and values equal to zero indicate no correlation between the tested methods.

The level of significance established as a basis for decision was lower than 5% ($p<0.05$) for all tests.

The study was approved by the Research Ethics Committee of Medical Sciences at Unicamp in December 2010, under protocol n. 872/2010.
Results

We evaluated 79 patients, being 39 (49.4%) female and 40 (50.6%) male, aged between 10 and 18 years (mean 12.8), who attended the Child and Adolescent Obesity Outpatient Clinic of Hospital de Clínicas da Unicamp.

The HS diagnosed by abdominal ultrasonography was present in 16 patients (20.3%). The mean ALT, GGT, and ALP were significantly higher in patients with HS, as well as the HOMA-IR index. Indicators of body composition and lipid profile showed no significantly different among the groups with and without HS (Table 1).

Among the patients assessed, 23 (29.1%) presented IR, being 13 (56.5%) females and 10 (43.5%) males. Of the patients with diagnosis of IR, eight (34.8%) also had HS. The means for WC, BMI, SF and %BF were higher in patients who presented IR. Mean HDL-cholesterol was significantly lower in patients with IR (Table 2).

### Table 1 - Clinical and laboratory characteristics of obese patients with and without hepatic steatosis. Values presented as means and standard deviation

|                  | Hepatic steatosis | Total (n=79) | p-value |
|------------------|-------------------|--------------|---------|
|                  | Absent (n=63)     | Present (n=16) |         |
| Age (years)      | 12.9±2.4          | 12.1±1.9     | 12.8±2.3 | 0.254 |
| Waist circumference (cm) | 101.2±13.1        | 103.6±10.4   | 101.7±12.6 | 0.288 |
| Body mass index (kg/m²) | 31.9±5.3          | 32.6±5.1     | 32.0±5.26 | 0.661 |
| Body fat (%)     | 41.8±5.2          | 40.6±5.0     | 41.6±5.1  | 0.538 |
| Subcutaneous fat (cm) | 4.2±1.0            | 4.2±1.1      | 4.2±1.0  | 0.683 |
| Aspartate aminotransferase (nº x) | 0.5±0.2           | 0.6±0.4      | 0.5±0.2  | 0.638 |
| Alanine aminotransferase (nº x) | 0.6±0.5           | 1.1±0.9      | 0.7±0.6  | 0.011 |
| Gama-glutamyl transferase (nº x) | 0.7±0.5           | 1.0±0.4      | 0.8±0.5  | 0.008 |
| Alkaline phosphatase (nº x) | 0.7±0.2           | 0.8±0.3      | 0.7±0.2  | 0.047 |
| Fasting glucose (mg/dL) | 82.7±6.6           | 85.0±8.0     | 83.2±6.9 | 0.423 |
| Fasting insulin (uUI/mL) | 10.8±7.0           | 17.2±11.7    | 12.1±8.5 | 0.041 |
| HOMA-IR          | 2.2±1.4           | 3.7±2.8      | 2.5±1.9  | 0.038 |
| Total Cholesterol (mg/dL) | 164.0±42.0       | 157.0±32.0   | 163.0±40.0 | 0.678 |
| LDL-cholesterol (mg/dL) | 103.0±39.0       | 92.0±22.0    | 101.0±36.0 | 0.294 |
| HDL-cholesterol (mg/dL) | 43.0±9.0          | 38.0±9.0     | 42.0±9.0 | 0.067 |
| Triglycerides (mg/dL) | 92.0±37.0         | 134.0±87.0   | 101.0±54.0 | 0.097 |
| Hepatic fat content | 52.49±3.46        | 68.56±5.90   | 55.7±27.4 | 0.031 |

Mann-Whitney test for all variables; nº x: number of times the upper limit of normality according to age and sex; HOMA-IR: Homeostasis Model Assessment–Insulin Resistance

### Table 2 - Characteristics of individuals evaluated according to insulin resistance

|                  | Insulin resistance | p-value |
|------------------|--------------------|---------|
|                  | Absent (n=56)     | Present (n=23) |         |
| Age (years)      | 12.8±2.46         | 12.84±2.14  | 0.750   |
| Waist circumference (cm) | 98.7±11.2        | 109.0±13.1  | 0.002   |
| Body mass index (kg/m²) | 30.6±4.61        | 35.39±5.33  | 0.001   |
| Body fat (%)     | 40.3±5.1          | 44.7±3.6    | 0.001   |
| Subcutaneous fat (cm) | 4.0±0.97         | 4.8±1.15    | 0.003   |
| Aspartate aminotransferase (nº x) | 0.5±0.23          | 0.61±0.34   | 0.775   |
| Alanine aminotransferase (nº x) | 0.7±0.56         | 0.9±0.83    | 0.065   |
| Gama-glutamyl transferase (nº x) | 0.7±0.45         | 1.0±0.69    | 0.043   |
| Alkaline Phosphatase (nº x) | 0.7±0.28         | 0.7±0.27    | 0.514   |
| Total cholesterol (mg/dL) | 165.0±45.0       | 158.0±25.0  | 0.456   |
| LDL-cholesterol (mg/dL) | 102.0±41.0       | 98.0±20.0   | 0.706   |
| HDL-cholesterol (mg/dL) | 44.0±9.0         | 38.0±8.0    | 0.006   |
| Triglycerides (mg/dL) | 95.0±56.0        | 114.0±47.0  | 0.051   |

nº x: number of times the upper limit of normal according to age and sex; Mann-Whitney test for all variables
Biochemical, anthropometric and body composition indicators as predictors of hepatic steatosis in obese adolescents

Table 3 - Effectiveness of biochemical, anthropometric, and body composition indicators and of the liver fat index in identifying hepatic steatosis

| Indicator                              | AAC±EP (95%CI)         | p-value | Cutoff Point | ST   | SP   |
|----------------------------------------|------------------------|---------|--------------|------|------|
| Alanine aminotransferase (nº x)       | 0.707±0.064 (0.581–0.832) | 0.011   | 0.54         | 93.7 | 49.2 |
| Aspartate aminotransferase (nº x)     | 0.538±0.084 (0.373–0.703) | 0.639   | –            | –    | –    |
| Gama-glutamyl transferase (nº x)      | 0.715±0.074 (0.570–0.859) | 0.008   | 1.06         | 62.5 | 80.9 |
| Alkaline phosphatase (nº x)           | 0.662±0.083 (0.499–0.825) | 0.047   | 0.81         | 56.2 | 74.6 |
| Fasting glycemia (mg/dL)              | 0.565±0.080 (0.408–0.721) | 0.424   | –            | –    | –    |
| Insulin (uUI/mL)                      | 0.666±0.081 (0.508–0.825) | 0.041   | 17.10        | 50.0 | 82.5 |
| HOMA-IR                               | 0.669±0.080 (0.512–0.826) | 0.038   | 3.28         | 50.0 | 80.9 |
| Total Cholesterol (mg/dL)             | 0.466±0.074 (0.320–0.612) | 0.678   | –            | –    | –    |
| HDL-cholesterol (mg/dL)               | 0.649±0.087 (0.477–0.820) | 0.067   | –            | –    | –    |
| LDL-cholesterol (mg/dL)               | 0.415±0.069 (0.279–0.550) | 0.294   | –            | –    | –    |
| Triglycerides (mg/dL)                 | 0.635±0.089 (0.460–0.810) | 0.683   | –            | –    | –    |
| Waist circumference (cm)              | 0.586±0.074 (0.440–0.732) | 0.289   | –            | –    | –    |
| Body mass index(kg/m²)                | 0.536±0.076 (0.386–0.686) | 0.661   | –            | –    | –    |
| Body fat (%)                          | 0.450±0.075 (0.303–0.597) | 0.538   | –            | –    | –    |
| Subcutaneous fat (cm)                 | 0.467±0.085 (0.300–0.633) | 0.683   | –            | –    | –    |
| Hepatic fat content                   | 0.675±0.71 (0.536–0.815)  | 0.003   | 56           | 81.2 | 55.5 |

AUC: area under the curve; SE: standard error; ST: sensitivity; SP: specificity; 95%CI: confidence interval of 95%; nº x: number of times the upper limit of normal according to age and sex; HOMA-IR: Homeostasis Model Assessment–Insulin Resistance

In the analysis of the ROC curve, liver enzymes (ALT, GG, T and ALP), HOMA-IR index, and FLI showed areas under the curve (AUC) significant (p<0.05) for the prediction of HS (Table 3). On the other hand, anthropometric and body composition indicators, plasma lipid profile, fasting glucose, and AST showed no significant results. The most accurate cutoff points for variables with significant results are shown in Table 3.

The concordance analysis between the diagnoses of HS by US and by FLI demonstrated a kappa index of 0.23, indicating little agreement between the methods. The chi-square test showed a correlation between both methods for the diagnosis of HS (6.924; p<0.009). Adolescents with a diagnosis of HS by FLI were five times more likely to show the HS by US. (OR 5.42; 95%CI 1.404–20.898).

Discussion

The present study found a prevalence of HS of 20.3% in the studied population. The prevalence of HS is poorly understood and it may be related to the method used for diagnosis. The studies used elevated ALT levels as a criterion or the comparison of the echogenicity of the hepatic parenchyma with the renal cortex, the latter being more hyperechogenic in relation to the adjacent kidney. Studies show prevalence in obese children and adolescents from 15 to 42%[11,12]. The prevalence of NAFLD more than doubled in the past 20 years, rising from 3.9% in 1988 to 10.7% in 2010 in U.S. adolescents[13]. Based on autopsy studies, Schwimmer et al[14] reported that the prevalence of HS in children and adolescents was of 9.6% and this prevalence rose to 38% in obese individuals. The difference in prevalence may be related to the degree of obesity, because in some studies with higher prevalence, mean BMI values are higher compared to studies with lower prevalence.

Abdominal ultrasonography is considered a good method for the diagnosis and monitoring of the degree of fatty infiltration in the liver, although it does not correlate with the degree of fibrosis. We adopted this method of image due to the good sensitivity (89%) and specificity (94%) for detection of HS compared to liver biopsy, considered as the gold standard[15], besides having a relatively low cost, being noninvasive, easy to apply, and available in most services.
The prevalence of IR assessed by the HOMA-IR index, found in this study was 29.1%. Published data reported prevalence rates higher in obese adolescents. This variation in the prevalence of IR in the studies may be explained by the lack of an established cutoff point as a reference to classify patient outcomes.

HS seems to relate directly to IR. The mean for the HOMA-IR index in this study was significantly higher in patients with HS. The HOMA-IR was shown to be a good indicator in predicting HS, with a cutoff of 3.28, close to that used for diagnosing IR (HOMA-IR >3.16). There is increasing evidence that obesity and IR are risk factors for NAFLD also in children and adolescents. Seixas demonstrated that obese children and adolescents with SH are 2.6-fold more likely to present IR when compared with children without HS. El-Koofy observed that the prevalence of IR was significantly higher in patients with HS compared with patients without HS (73 versus 28%).

Insulin resistance and oxidative stress appear to be the two events involved in the pathogenesis of NAFLD. The pathophysiology involves two steps: first, IR causes steatosis; in the second, oxidative stress produces lipid peroxidation and active inflammatory cytokines, resulting in steatohepatitis. The state of insulin resistance, often associated with obesity, leads to increased circulating free fatty acids that are seized and deposited within hepatocytes. This deposit activates the inflammatory cascade modulated by a variety of cytokines, and results in the exacerbation of oxidative stress, critical to the progression of NAFLD. This hypothesis was confirmed in the study by Ruiz-Extremera et al., in which it was observed in obese adolescents, that oxidative stress and IR are significant factors for the development of HS. Maget et al. suggest that in all children and adolescents with overweight and obesity and that present IR, HS should be investigated.

In the comparison of means between groups with and without HS, the results of liver enzymes ALT, ALP, and GGT, presented as the number of times the upper limit of normal values, showed significant values. In the analysis of the ROC curve, the GGT showed greater specificity in the prediction of the HS, with a cutoff point 1.06 times higher than the reference value. ALT showed greater sensitivity, with a cutoff of 0.54 times — value below the reference value. As the cutoff is defined as the highest sum of sensitivity and specificity, when the cutoff of ALT rises to 1, the sensitivity decreases to 31.2%, indicating not being a good predictor of HS. The study by Ramos corroborates the findings in the present study. In his research, the mean values of GGT were also associated to HS, but no enzyme presented a good cutoff point to predict the HS. The author also highlights the importance of performing ultrasonography in children and adolescents as a criterion to evaluate HS.

Some studies have shown that changes in ALT and GGT can relate to some degree of liver inflammation, characterizing a more advanced stage of NAFLD. Therefore, it is recommended that even in the absence of changes in serum levels of liver enzymes, the ultrasound integrates the overall assessment of the obese patient to identify mild cases of hepatic fatty infiltration.

The means of anthropometric indicators and body composition, and lipid profile showed no significant difference between groups, and neither did the ROC curve analysis. This can be explained by the fact that patients in this study were from a clinic that treats severe cases of obesity, all of which with BMI, WC, and %BF above the recommended, regardless of HS. El-Koofy et al. observed a significant difference in the means of groups with and without HS for BMI, WC, and lipid profile. However, it is noteworthy that liver biopsy was the method used for the diagnosis of NAFLD and that, as inclusion criteria, all patients had to present hepatomegaly and/or abnormalities on ALT, indicating a more advanced stage of liver disease. The authors diagnosed 44% of patients with NAFLD, a much higher prevalence than that found in the present study. In contrast, the results of Duarte and Silva and Lin et al. agree with the present study, with no significant difference in lipid profile between groups with and without HS.

The FLI showed little relation to the diagnosis of HS by US. This index uses three variables for the calculation (GGT, TG and WC), and two of these variables (TG and WC) showed no statistical difference between the groups with and without HS, which could be the explanation for the poor agreement between the methods. This is the first study that made reference to FLI in obese adolescents and due to the low concordance with the US, it was considered of little use in the studied population.

In conclusion, patients with elevated GGT and/or HOMA-IR >3.28 should undergo US examination with great probability of obtaining HS as a result. The FLI showed little association with the US, proving not to be a good method for the diagnosis of HS in obese adolescents.
References

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
2. Roberts EA. Non-alcoholic steatohepatitis in children. Clin Liver Dis 2007;11:155-72.
3. Sathyam P, Martin S, Alvarez F. Nonalcoholic fatty liver disease (NAFLD) in children. Curr Opin Pediatr 2002;14:593-600.
4. World Health Organization [homepage on the Internet]. Geneva: Growth reference 5-19 years [cited 2013 Jan 10]. Available from: http://www.who.int/growthref/en/
5. Lohman GT, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign: Human Kinetics; 1988.
6. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:500-3.
7. Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound 1996;24:25-9.
8. Diniz AL, Tomé RA, Debs CL, Carraro R, Roever LB, Pinto RM. Reproducibility of ultrasonography as a method to measure abdominal and visceral fat. Radiol Bras 2009;42:353-7.
9. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006;6:3-7.
10. Roche Diagnostics [homepage on the Internet]. Reference ranges for adults and children [cited 2013 Jan 10]. Available from: https://www.rochediagnostics.fr/Htdocs/media/pdf/actualites/2a_Reference_Ranges_2008.pdf
11. Gupta R, Shengo A, Matthews NA, Anhalt H, Matta Y, Lamicchane B et al. The prevalence of non-alcoholic fatty liver disease and metabolic syndrome in obese children. J Pediatr Endocrinol Metab 2011;24:907-11.
12. Duarte MA, Silva GA. Steatohepatitis in obese children and adolescents. J Pediatr (Rio J) 2011;87:150-6.
13. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013;162:496-500.
14. Schwimmer JB, Deutsch R, Kahn T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93.
15. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-5.
16. Caceres M, Teran CG, Rodriguez S, Medina M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. BMC Pediatr 2008;8:31.
17. Medeiros CC, Ramos AT, Cardoso MA, França IS, Cardoso AS, Gonzaga NC et al. Insulin resistance and its association with metabolic syndrome components. Arq Bras Cardiol 2011;97:380-9.
18. Madeira IR, Carvalho CN, Gazolla FM, de Matos HJ, Borges MA, Bordallo MA. Cut-off point for homeostatic model assessment for insulin resistance (HOMA-IR) index established from receiver operating characteristic (ROC) curve in the detection of metabolic syndrome in overweight pre-pubertal children. Arq Bras Endocrinol Metab 2008;52:1468-73.
19. Seixas RB. Avaliação da esteatose hepática em crianças e adolescentes obesos e com sobrepeso e sua associação com a resistência à insulina [tese de mestrado]. Brasília (DF): UnB; 2010.
20. El-Koofy NM, Anwar GM, El-Raziky MS, El-Hennawy AM, El-Mougy FM, El-Karakasy HM et al. The association of metabolic syndrome, insulin resistance and non-alcoholic fatty liver disease in overweight/obese children. Saudi J Gastroenterol 2012;18:44-9.
21. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002;34:255-62.
22. Ruiz-Extremera Á, Carazo Á, Salmerón A, León J, Casado J, Goicoechea A et al. Factors associated with hepatic steatosis in obese children and adolescents. J Pediatr Gastroenterol Nutr 2011;53:196-201.
23. Mager DR, Ling S, Roberts EA. Anthropometric and metabolic characteristics in children with clinically diagnosed nonalcoholic fatty liver disease. Paediatri Child Health 2008;13:111-7.
24. Ramos AL. Esteatose hepática em crianças e adolescentes com excesso de peso: relação com os componentes da síndrome metabólica [tese de mestrado]. Campina Grande (PB): UEPB; 2011.
25. Fishbein MH, Miner M, Mogren C, Chalekson J. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003;36:54-61.
26. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a “growing” problem. J Hepatol 2007;46:1133-42.
27. Lin YC, Chang PF, Yeh SJ, Liu K, Chen HC. Risk factors for liver steatosis in obese children and adolescents. Pediatr Neonatol 2010;51:149-54.